A detailed history of Royal Bank Of Canada transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 7,923 shares of TVTX stock, worth $143,327. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,923
Previous 7,544 5.02%
Holding current value
$143,327
Previous $62,000 77.42%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.89 - $15.21 $2,990 - $5,764
379 Added 5.02%
7,923 $110,000
Q2 2024

Aug 14, 2024

BUY
$5.26 - $8.28 $20,966 - $33,004
3,986 Added 112.03%
7,544 $62,000
Q1 2024

Nov 05, 2024

SELL
$7.18 - $9.82 $28,619 - $39,142
-3,986 Reduced 52.84%
3,558 $27,000
Q1 2024

May 15, 2024

SELL
$7.18 - $9.82 $138,423 - $189,319
-19,279 Reduced 84.42%
3,558 $27,000
Q4 2023

Feb 14, 2024

BUY
$5.44 - $9.5 $71,541 - $124,934
13,151 Added 135.77%
22,837 $205,000
Q3 2023

Nov 14, 2023

BUY
$7.64 - $17.25 $15,516 - $35,034
2,031 Added 26.53%
9,686 $86,000
Q2 2023

Aug 14, 2023

BUY
$15.3 - $22.61 $26,499 - $39,160
1,732 Added 29.24%
7,655 $117,000
Q1 2023

May 15, 2023

SELL
$17.82 - $22.89 $121,478 - $156,041
-6,817 Reduced 53.51%
5,923 $133,000
Q4 2022

Feb 14, 2023

BUY
$18.47 - $26.14 $175,298 - $248,094
9,491 Added 292.12%
12,740 $267,000
Q3 2022

Nov 14, 2022

SELL
$22.91 - $28.63 $64,514 - $80,622
-2,816 Reduced 46.43%
3,249 $80,000
Q2 2022

Aug 15, 2022

SELL
$20.94 - $30.01 $1,005 - $1,440
-48 Reduced 0.79%
6,065 $147,000
Q1 2022

May 16, 2022

SELL
$23.61 - $30.6 $163,499 - $211,905
-6,925 Reduced 53.11%
6,113 $157,000
Q4 2021

Feb 14, 2022

BUY
$24.34 - $31.17 $115,176 - $147,496
4,732 Added 56.97%
13,038 $405,000
Q3 2021

Nov 15, 2021

BUY
$12.98 - $25.03 $55,203 - $106,452
4,253 Added 104.93%
8,306 $201,000
Q2 2021

Aug 16, 2021

BUY
$14.11 - $26.4 $57,187 - $106,999
4,053 New
4,053 $59,000

Others Institutions Holding TVTX

About Travere Therapeutics, Inc.


  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $1.16B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.